SV2017005380A - Tratamientos conjuntos con anticuerpos anti cd40 - Google Patents

Tratamientos conjuntos con anticuerpos anti cd40

Info

Publication number
SV2017005380A
SV2017005380A SV2017005380A SV2017005380A SV2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A SV 2017005380 A SV2017005380 A SV 2017005380A
Authority
SV
El Salvador
Prior art keywords
treatments
antibodies
joint
joint treatments
antigen
Prior art date
Application number
SV2017005380A
Other languages
English (en)
Inventor
Peter Ellmark
Per Norlen
Niina Veitonmäki
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2017005380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of SV2017005380A publication Critical patent/SV2017005380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A TRATAMIENTOS CONJUNTOS PARA TRATAR UN TUMOR SÓLIDO EN UN SUJETO. LOS TRATAMIENTOS CONJUNTOS COMPRENDEN (A) UN ANTICUERPO, O LA PORCIÓN DE FIJACIÓN AL ANTÍGENO DE ESTE, QUE SE FIJA ESPECÍFICAMENTE A CD40, Y (B) UN AGENTE INMUNOTERAPÉUTICO ADICIONAL CON EFICACIA EN EL TRATAMIENTO DEL CÁNCER, EN DONDE EL AGENTE NO ES UN ANTICUERPO ANTI-CD4O NI EL FRAGMENTO DE FIJACIÓN AL ANTÍGENO DE ESTE. LA INVENCIÓN TAMBIÉN SE REFIERE A KITS Y MÉTODOS PARA USAR TALES TRATAMIENTOS
SV2017005380A 2014-08-12 2017-02-07 Tratamientos conjuntos con anticuerpos anti cd40 SV2017005380A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies

Publications (1)

Publication Number Publication Date
SV2017005380A true SV2017005380A (es) 2018-09-14

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005380A SV2017005380A (es) 2014-08-12 2017-02-07 Tratamientos conjuntos con anticuerpos anti cd40

Country Status (25)

Country Link
US (3) US11149090B2 (es)
EP (2) EP3180087B1 (es)
JP (1) JP6654187B2 (es)
KR (1) KR102443258B1 (es)
CN (2) CN106573981A (es)
AU (1) AU2015303164B2 (es)
CA (1) CA2957146A1 (es)
CL (1) CL2017000335A1 (es)
CO (1) CO2017001317A2 (es)
CR (1) CR20170096A (es)
DK (1) DK3180087T3 (es)
EA (1) EA201790339A1 (es)
EC (1) ECSP17008984A (es)
ES (1) ES2725463T3 (es)
IL (1) IL250512B (es)
MA (1) MA47472A (es)
MX (1) MX2017001864A (es)
NI (1) NI201700015A (es)
NZ (1) NZ729270A (es)
PE (1) PE20170680A1 (es)
PH (1) PH12017500229A1 (es)
SG (1) SG11201701070WA (es)
SV (1) SV2017005380A (es)
UA (1) UA119783C2 (es)
WO (1) WO2016023960A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3508500A1 (en) 2011-04-29 2019-07-10 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EP2953634B1 (en) 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
CN108473585B (zh) 2015-11-18 2022-04-05 默沙东公司 Pd1和/或lag3结合剂
EP3389714A4 (en) 2015-12-14 2019-11-13 MacroGenics, Inc. BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
CN117903308A (zh) * 2016-05-13 2024-04-19 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
MX2018015853A (es) 2016-07-14 2019-08-21 Genmab As Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
JP7265989B2 (ja) 2016-10-25 2023-04-27 ウロゲン ファーマ リミテッド 体腔の免疫調節治療
JP2019534292A (ja) * 2016-11-02 2019-11-28 アペクシジェン， インコーポレイテッド 組み合わせた抗ｃｄ４０抗体および使用方法
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
WO2018129714A1 (zh) * 2017-01-13 2018-07-19 杭州翰思生物医药有限公司 抗pd-1的单克隆抗体及其应用
EP3589324A1 (en) * 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
WO2019043170A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh POLY THERAPY BASED ON HSP70
BR112020018761A2 (pt) * 2018-03-13 2020-12-29 Hibercell, Inc. Imunoterapia combinada com beta-glucano e agonista de cd40
WO2019241306A2 (en) * 2018-06-12 2019-12-19 Neon Therapeutics, Inc. Combination therapy with neoantigen vaccine
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
US20220000998A1 (en) 2018-11-23 2022-01-06 Strike Pharma Ab Bi-specific conjugates
KR20210099027A (ko) * 2018-11-30 2021-08-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
SG11202112909SA (en) * 2019-05-28 2021-12-30 Janssen Biotech Inc Method of providing safe administration of an anti-cd40 antibody
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021132936A1 (ko) * 2019-12-27 2021-07-01 인터올리고 주식회사 암 치료용 면역 항암 조성물
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023064878A1 (en) * 2021-10-15 2023-04-20 The Rockefeller University Combination of anti-cd40 antibody and il-15 for treating cancer
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
AU2002234572B2 (en) 2000-12-12 2006-07-06 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
PT1391464E (pt) 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
EP1761311A2 (en) 2004-04-27 2007-03-14 Novartis Vaccines and Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
AU2006249305B2 (en) 2005-05-26 2012-10-18 Genentech, Inc. Humanized anti-CD40 antibodies and their methods of use
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8551485B2 (en) 2008-01-23 2013-10-08 Xencor, Inc. Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
JP2012501323A (ja) * 2008-08-29 2012-01-19 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
WO2015091655A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Combination therapy with an anti-ang2 antibody and a cd40 agonist
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112017021688A2 (pt) 2015-04-17 2018-08-14 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
MX2017015143A (es) 2015-05-29 2018-03-28 Abbvie Inc Anticuerpos anti-cd40 y sus usos.
PE20180315A1 (es) 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью

Also Published As

Publication number Publication date
US11149090B2 (en) 2021-10-19
AU2015303164A1 (en) 2017-03-09
US20240132609A1 (en) 2024-04-25
EP3552665A3 (en) 2019-12-18
PH12017500229A1 (en) 2017-07-10
JP6654187B2 (ja) 2020-02-26
ES2725463T3 (es) 2019-09-24
US20170226217A1 (en) 2017-08-10
CL2017000335A1 (es) 2017-08-11
CN114099671A (zh) 2022-03-01
NI201700015A (es) 2017-05-12
ECSP17008984A (es) 2017-05-31
CO2017001317A2 (es) 2017-08-10
EP3552665A2 (en) 2019-10-16
JP2017524715A (ja) 2017-08-31
IL250512B (en) 2021-08-31
CA2957146A1 (en) 2016-02-18
UA119783C2 (uk) 2019-08-12
EP3180087B1 (en) 2019-03-13
SG11201701070WA (en) 2017-03-30
IL250512A0 (en) 2017-03-30
WO2016023960A1 (en) 2016-02-18
KR20170041790A (ko) 2017-04-17
AU2015303164B2 (en) 2020-10-29
NZ729270A (en) 2024-03-22
US20210403589A1 (en) 2021-12-30
CN106573981A (zh) 2017-04-19
PE20170680A1 (es) 2017-06-14
MA47472A (fr) 2019-12-18
EA201790339A1 (ru) 2017-06-30
MX2017001864A (es) 2017-08-02
DK3180087T3 (da) 2019-05-13
BR112017002729A2 (pt) 2018-02-27
CR20170096A (es) 2017-06-15
EP3180087A1 (en) 2017-06-21
KR102443258B1 (ko) 2022-09-14

Similar Documents

Publication Publication Date Title
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CO2018000809A2 (es) Anticuerpos para cd40
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
AR101740A1 (es) Terapia de combinación y composiciones
EA201791736A1 (ru) Комбинированная терапия для лечения рака
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
BR112019008241A2 (pt) tratamento do prurigo nodular
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека